Metraipolis › archive › dc_2374403c86cd
FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook — Europe PMC PMID:42324661
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42324661
- DOI
- 10.1080/15476286.2026.2689117
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T07:17:42.488Z
- SHA-256 of the archived text
7fc87c2268205dd617aec137eb852641d20697688b3976e50afdd2c7efac2436- Stable URL of this page
https://metraipolis.com/documento/dc_2374403c86cd
How to cite
FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook — Europe PMC PMID:42324661 — Europe PMC (en), https://europepmc.org/article/MED/42324661 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2374403c86cd (Metraipolis archive dc_2374403c86cd, sha256 7fc87c2268205dd617aec137eb852641d20697688b3976e50afdd2c7efac2436)
BibTeX
@misc{dc2374403c86cd,
title = {FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook — Europe PMC PMID:42324661},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42324661},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2374403c86cd; sha256 7fc87c2268205dd617aec137eb852641d20697688b3976e50afdd2c7efac2436},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42324661. Agents can read the archived copy with the MCP tool read_document.